Target intelligence / Profile preview

Fragile X messenger ribonucleoprotein 1 (FMRP)

Target
FMRP
Molecular classification
RNA binding protein, Translational regulator, Other
01

Overview

Fragile X messenger ribonucleoprotein 1 (FMRP) is an RNA-binding protein encoded by the FMR1 gene on the X chromosome, with critical roles in synaptic function, neuronal development, and cognitive processes. FMRP regulates the translation, transport, and localization of mRNAs, especially in neurons, where it is essential for normal synaptic plasticity. Loss or mutation of FMR1 causes fragile X syndrome, the most common inherited cause of intellectual disability, and is associated with a spectrum of neurodevelopmental and neurodegenerative disorders, including autism and premature ovarian failure. FMRP exerts translational repression on key targets involved in synaptic structure and function, influencing local protein synthesis in response to synaptic activity, with its activity tightly regulated by metabotropic glutamate receptor (mGluR) signaling.

Other names
FMR1Fragile X mental retardation proteinfragile X messenger RNA binding protein
02

Mechanism of action

Not applicable for direct targeting; when targeted indirectly, drugs modulate synaptic protein synthesis via mGluR signaling pathways affected by loss of FMRP function

03

Biological functions

Regulation of synaptic plasticityTranslational repressionRNA transport and localizationDNA damage responseRegulation of local protein synthesis in neurons
04

Disease associations

Neurodevelopmental disorder (e.g., fragile X syndrome, intellectual disability, autism)Premature ovarian failureNeurodegenerative disease (e.g., Parkinson's disease)Developmental delays
05

Safety considerations

Gene therapies or interventions targeting FMR1 must consider off-target effects, risks of altered synaptic function, and neurodevelopmental impact
06

Interacting drugs

None established for direct interaction; some research on targeting upstream or downstream pathways (such as metabotropic glutamate receptor antagonists) is ongoing, but FMRP itself is not currently a direct drug target
07

Biomarkers

FMR1 CGG repeat expansion (genetic test for carrier or diagnosis)FMRP protein levels (biomarker for fragile X syndrome and related conditions)

Beyond the preview

Go deeper on Fragile X messenger ribonucleoprotein 1 (FMRP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fragile X messenger ribonucleoprotein 1 (FMRP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call